Author of

• 13420

  +

  P1.01 - Poster Session/ Treatment of Advanced Diseases – NSCLC (ID 206)

  • Event: WCLC 2015
  • Type: Poster
  • Track: Treatment of Advanced Diseases - NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 9/07/2015, 09:30 - 17:00, Exhibit Hall (Hall B+C)

  • 13426

    +

    P1.01-006 - Targeted Drug Selection for Advanced NSCLC Treatment (ID 389)

    09:30 - 09:30  |  Author(s): J. Ni
    • Abstract
    • Slides

    Background:
    The efficacy of traditional cytotoxic drugs that treat the Advanced Non-Small Cell Lung Cancer (ANSCLC) has reached a plateau. Recently, the targeted therapy has become a new option for ANSCLC treatment. The most representative targeted therapy is tyrosine kinase inhibitor (TKI) aimed at the genetic mutations of epidermal growth factor (EGFR). Currently, three TKI drugs, namely Gefitinib, Erlotinib, and Icotinib, are available in Chinese market. This article compared the molecular structure，pharmacokinetic parameters, clinical data, adverse reactions, and contraindications of the three drugs to guide the optimal selection in clinical practice.
    
    Methods:
    Not Applicable.
    
    Results:
    Not Applicable.
    
    Conclusion:
    Presently the pros and cons of the three drugs are inconclusive. Taken together, TKI can be used as the first-line drug among patients with EGFR mutations. Of these TKIs, Gefitinib is convenient and safe with fair tolerability, and consequently recommended. Icotinib needs to be administered t.i.d without meal. However, in ICOGEN study, it was safer than Gefitinib, and therefore also recommended. Erlotinib needs to be taken without meal, requires quitting smoke and has narrow therapeutic windows. The occurrence rate and severity of its adverse reactions are relatively high. Therefore Erlotinib is not recommended. Among the non-selective patients, TKI can be used as the second- or third-line treatment. Erlotinib apparently has better survival benefit and therefore is recommended. Icotinib has certain efficacy among the Acian female non-smokers with adenocarcinoma or lung adenocarcinoma. Its safety and tolerability are the best. Therefore, Icotinib is the next recommended drug. Gefitinib only has certain efficacies among the Asian female nonsmoking lung adenocarcinoma patients, and therefore is recommended to only the appropriate population.
    
    

    Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.